
NYSEReal EstateReal Estate - Services
Latest quote
$0.9197
+$0.0197 · +2.19%
Rafael Holdings, Inc. holds strategic investments in both early-stage and clinical pharmaceutical companies, alongside a portfolio of commercial real estate assets situated in the United States and Israel. The company's business activities are structured into two primary divisions: Pharmaceuticals and Real Estate. Its Real Estate segment manages and leases a commercial office complex, which features an integrated 800-space public parking facility. The Pharmaceutical division, conversely, focuses on developing and bringing to market therapies designed to capitalize on the metabolic distinctions between healthy cells and malignant ones. The firm's flagship drug candidate is CPI-613 (devimistat), currently undergoing evaluation in numerous clinical trials, including two pivotal Phase III registrational studies for the treatment of advanced pancreatic cancer and relapsed/refractory acute myeloid leukemia. Rafael Holdings, Inc. is headquartered in Newark, New Jersey.
Previous close
$0.9197
+$0.0197 · +2.19%
Regular session · ET · Market data may be delayed.
Rafael Holdings, Inc. holds strategic investments in both early-stage and clinical pharmaceutical companies, alongside a portfolio of commercial real estate assets situated in the United States and Israel. The company's business activities are structured into two primary divisions: Pharmaceuticals and Real Estate. Its Real Estate segment manages and leases a commercial office complex, which features an integrated 800-space public parking facility. The Pharmaceutical division, conversely, focuses on developing and bringing to market therapies designed to capitalize on the metabolic distinctions between healthy cells and malignant ones. The firm's flagship drug candidate is CPI-613 (devimistat), currently undergoing evaluation in numerous clinical trials, including two pivotal Phase III registrational studies for the treatment of advanced pancreatic cancer and relapsed/refractory acute myeloid leukemia. Rafael Holdings, Inc. is headquartered in Newark, New Jersey.
Day range
Current $0.9197
52-week range
Current $0.9197
Regular session · ET · Market data may be delayed.
GoAI Score
Hold
Valuation
53
Fair Value
Sentiment
60
Mixed
Risk
62
High Risk
Momentum
72
Gaining
Full GoAI research
Thesis, catalysts, evidence, and risk analysis.
Rafael Holdings, Inc. holds strategic investments in both early-stage and clinical pharmaceutical companies, alongside a portfolio of commercial real estate assets situated in the United States and Israel. The company's business activities are structured into two primary divisions: Pharmaceuticals and Real Estate. Its Real Estate segment manages and leases a commercial office complex, which features an integrated 800-space public parking facility. The Pharmaceutical division, conversely, focuses on developing and bringing to market therapies designed to capitalize on the metabolic distinctions between healthy cells and malignant ones. The firm's flagship drug candidate is CPI-613 (devimistat), currently undergoing evaluation in numerous clinical trials, including two pivotal Phase III registrational studies for the treatment of advanced pancreatic cancer and relapsed/refractory acute myeloid leukemia. Rafael Holdings, Inc. is headquartered in Newark, New Jersey.
Day range
Current $0.9197
52-week range
Current $0.9197
Profitability as a percentage of reported revenue.
Revenue
Operating income
Net income
| Metric (USD) | FY2026 | FY2025 | FY2024 | FY2023 | FY2022 |
|---|---|---|---|---|---|
| Revenue | 874K USD | 917K USD | 637K USD | 279K USD | 410K USD |
| Cost of goods sold | 246K USD | 422K USD | 154K USD | — | — |
| Gross profit | 628K USD | 495K USD | 483K USD | 279K USD | 410K USD |
| Research and development | 24.33M USD | 12.82M USD | 94.03M USD | 6.31M USD | 8.74M USD |
| Selling, general, and administrative | 9.7M USD | 13.78M USD | 8.85M USD | 8.93M USD | 16.98M USD |
| Operating expenses | 34.04M USD | 26.6M USD | 103.11M USD | 15.32M USD | 60.89M USD |
| Interest income | 1.24M USD | 2M USD | 2.38M USD | 3.25M USD | 201K USD |
| Interest expense | 333K USD | 658K USD | 248K USD | — | 6K USD |
| Depreciation and amortization | 204K USD | 288K USD | 225K USD | 78K USD | 72K USD |
| Operating income | −33.41M USD | −26.11M USD | −102.63M USD | −15.04M USD | −60.48M USD |
| Net income | −29.64M USD | −30.52M USD | −34.41M USD | −1.88M USD | −124.66M USD |
Company facts updated Nov 22, 2026.
Recent quarterly results
Recent quarterly results
| Action | Ex-dividend date | Details | Record date | Payment date |
|---|---|---|---|---|
Dividend | Dec 18, 2009 | $0.02Semi-Annual | — | Dec 31, 2009 |
Dividend | Jun 19, 2009 | $0.02Semi-Annual | — | Jun 30, 2009 |
Ex-dividend Dec 18, 2009
$0.02
Semi-Annual
Payment Dec 31, 2009
Ex-dividend Jun 19, 2009
$0.02
Semi-Annual
Payment Jun 30, 2009
Funds reporting this stock among their holdings, ordered by reported position size.
Vanguard Morningstar Total Stock Market ETFVTI830.34K0.00%689.3B USD0.03%$340.02-3.52%
Vanguard Extended Market ETFVXF360.89K0.00%30.2B USD0.05%$211.44-3.21%
iShares Micro-Cap ETFIWC91.44K0.01%1.09B USD0.60%$157.87-3.19%
U.S. Micro Cap Portfolio ETFDFMC83.44K0.00%7.03B USD0.43%$54.21-2.39%
Dimensional - US Small Cap ETFDFAS40.29K0.00%31.24B USD0.30%$74.24-2.48%
Dimensional - US Core Equity 2 ETFDFAC32.8K0.00%80.74B USD0.21%$41.36-2.91%
U.S. Vector Equity Portfolio ETF Class SharesDXUV21.56K0.00%5.79B USD0.26%$63.54-2.92%
U.S. Core Equity 1 Portfolio ETF Class SharesDCOR17.73K0.00%41.43B USD0.17%$76.93-3.10%
Vanguard Morningstar Total Stock Market ETFVTI
Vanguard Extended Market ETFVXF
iShares Micro-Cap ETFIWC
U.S. Micro Cap Portfolio ETFDFMC
Dimensional - US Small Cap ETFDFAS
Dimensional - US Core Equity 2 ETFDFAC
U.S. Vector Equity Portfolio ETF Class SharesDXUV
U.S. Core Equity 1 Portfolio ETF Class SharesDCORAI-generated and delayed market data for informational and educational purposes only. Not investment advice.